The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Luteolin, an Abundant Dietary Component is a Potent Anti-leishmanial Agent that Acts by Inducing Topoisomerase II-mediated Kinetoplast DNA Cleavage Leading to Apoptosis
Open accessAbstract
BACKGROUND: Plant-derived flavonoids, which occur abundantly in our daily dietary intake, possess antitumor, antibacterial, and free radical scavenging properties. They form active constituents of a number of herbal and traditional medicines. Several flavonoids have been shown to exert their action by interacting with DNA topoisomerases and promoting site-specific DNA cleavage. Therefore, flavonoids are potential candidates in drug design. We report here that, although the flavonoids luteolin and quercetin are potent antileishmanial agents, luteolin has great promise for acting as a lead compound in the chemotherapy of leishmaniasis, a major concern in developing countries. MATERIALS AND METHODS: Kinetoplast DNA (kDNA) minicircle cleavage in drug-treated parasites was measured by electrophoresis of the total cellular DNA, followed by Southern hybridization using 32P labeled kDNA as a probe. Cell cycle progression and apoptosis were measured by flow cytometry using propidium iodide and fluorescein isothiocyanate (FITC)-labeled Annexin V. RESULTS: Luteolin and quercetin inhibited the growth of Leishmania donovani promastigotes and amastigotes in vitro, inhibited DNA synthesis in promastigotes, and promoted topoisomerase-II-mediated linearization of kDNA minicircles. The IC50 values of luteolin and quercetin were 12.5 microM and 45.5 microM, respectively. These compounds arrest cell cycle progression in L. donovani promastigotes, leading to apoptosis. Luteolin has no effect on normal human T-cell blasts. Both luteolin and quercetin reduced splenic parasite burden in animal models. CONCLUSION: Luteolin and quercetin are effective antileishmanial agents. Quercetin has nonspecific effects on normal human T cells, but luteolin appears nontoxic. So, luteolin can be a strong candidate for antileishmanial drug design.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Martin, S. J., Reutelingsperger, C. P., McGahon, A. J., Rader, J. A., van Schie, R. C., LaFace, D. M., & Green, D. R. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.5.1545 · Cited by 2,824
Hertog, M. G. L., Hollman, P. C. H., Katan, M. B., & Kromhout, D. (1993) · Nutrition and Cancer · doi:10.1080/01635589309514267 · Cited by 1,216
Cited by
Distribution and biological activities of the flavonoid luteolin
Lopez-Lazaro, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787001712 · Cited by 1,106
“DNA topoisomerase (topo) inhibitors are efficient inducers of apoptosis in cancer cells [207] and several works have reported that luteolin inhibits and poisons topo I and topo II [117, 205, 208-213].”
BackgroundAnti-Oxidant, Anti-Inflammatory and Anti-Allergic Activities of Luteolin
Seelinger, G., Merfort, I., & Schempp, C. (2008) · Planta Medica · doi:10.1055/s-0028-1088314 · Cited by 558
Tasdemir, D., Kaiser, M., Brun, R., Yardley, V., Schmidt, T. J., Tosun, F., & Rüedi, P. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.50.4.1352-1364.2006 · Cited by 516
The Role of Quercetin, Flavonols and Flavones in Modulating Inflammatory Cell Function
Chirumbolo, S. (2010) · Inflammation & Allergy - Drug Targets · doi:10.2174/187152810793358741 · Cited by 319
Metadata
- Authors
- Mittra, B., Saha, A., Roy Chowdhury, A., Pal, C., Mandal, S., Mukhopadhyay, S., Bandyopadhyay, S., & Majumder, H. K.
- Venue
- Molecular Medicine
- Published
- 2000-06
- Volume
- 6
- Issue
- 6
- Pages
- 527-541
- ISSN
- 1076-1551 (ISSN-L)
- 1528-3658
- OpenAlex
- W1884411061
- Cited by
- 244
- References
- 2
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.